Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AEterna Zentaris appoints new president and CEO

This article was originally published in Scrip

Executive Summary

AEterna Zentaris has appointed Professor Jurgen Engel as president and CEO, effective September 1st. Professor Engel is currently executive vice-president and chief scientific officer at the company, and as president will focus on the development of AEterna Zentaris's pipeline, particularly for the company's lead compound for prostatic hyperplasia, cetrorelix. Dr Engel succeeds Juergen Ernst, who has been acting as interim president and CEO since April, and who will now take the role of executive chairman, also effective September 1st.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts